Literature DB >> 23006541

Influenza virus infects bone marrow mesenchymal stromal cells in vitro: implications for bone marrow transplantation.

Mahesh Khatri1, Yehia M Saif.   

Abstract

Mesenchymal stromal cells (MSCs) have differentiation, immunomodulatory, and self-renewal properties and are, therefore, an attractive tool for regenerative medicine and autoimmune diseases. MSCs may be of great value to treat graft-versus-host disease. Influenza virus causes highly contagious seasonal infection and occasional pandemics. The infection is severe in children, elderly, and immunocompromised hosts including hematopoietic stem cell transplant patients. The objective of this study was to determine if MSCs are permissive to influenza virus replication. We isolated MSCs from the bone marrow of 4- to 6-week-old germ-free pigs. Swine and human influenza virus strains were used to infect MSCs in vitro. MSCs expressed known influenza virus α-2,3 and α-2,6 sialic acid receptors and supported replication of swine and human influenza viruses. Viral infection of MSCs resulted in cell lysis and proinflammatory cytokine production. These findings demonstrate that bone marrow-derived MSCs are susceptible to influenza virus. The data also suggest that transplantation of bone marrow MSCs from influenza virus-infected donors may transmit infection to recipients. Also, MSCs may get infected if infused into a patient with an ongoing influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23006541     DOI: 10.3727/096368912X656063

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  15 in total

Review 1.  Role of epithelial sodium channels in the regulation of lung fluid homeostasis.

Authors:  Sadis Matalon; Rafal Bartoszewski; James F Collawn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

2.  Therapeutic potential of porcine bronchoalveolar fluid-derived mesenchymal stromal cells in a pig model of LPS-induced ALI.

Authors:  Mahesh Khatri; Levi A Richardson
Journal:  J Cell Physiol       Date:  2018-01-19       Impact factor: 6.384

3.  Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy.

Authors:  Jeffrey E Gotts; Jason Abbott; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-07-18       Impact factor: 5.464

4.  Tropism of avian influenza A (H5N1) virus to mesenchymal stem cells and CD34+ hematopoietic stem cells.

Authors:  Maytawan Thanunchai; Pumaree Kanrai; Suwimon Wiboon-Ut; Pilaipan Puthavathana; Suradej Hongeng; Arunee Thitithanyanont
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

5.  In reply.

Authors:  Anna Krasnodembskaya
Journal:  Stem Cells Transl Med       Date:  2020-04-22       Impact factor: 6.940

Review 6.  Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.

Authors:  Susan Moradinasab; Atieh Pourbagheri-Sigaroodi; Parisa Zafari; Seyed H Ghaffari; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2021-04-28       Impact factor: 5.714

7.  Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza.

Authors:  Ilyse Darwish; David Banner; Samira Mubareka; Hani Kim; Rickvinder Besla; David J Kelvin; Kevin C Kain; W Conrad Liles
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

8.  Porcine lung mesenchymal stromal cells possess differentiation and immunoregulatory properties.

Authors:  Mahesh Khatri; Timothy D O'Brien; Kuldeep S Chattha; Linda J Saif
Journal:  Stem Cell Res Ther       Date:  2015-11-11       Impact factor: 6.832

9.  Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model.

Authors:  Mahesh Khatri; Levi Arthur Richardson; Tea Meulia
Journal:  Stem Cell Res Ther       Date:  2018-01-29       Impact factor: 6.832

Review 10.  Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.

Authors:  Maroun Khoury; Jimena Cuenca; Fernanda F Cruz; Fernando E Figueroa; Patricia R M Rocco; Daniel J Weiss
Journal:  Eur Respir J       Date:  2020-06-04       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.